PROTACs offer great potential to overcome the RT resistance of tumor cells by targeting, for example, receptors like EGFR, androgen (AR) and estrogen receptor (ER), or kinases, including CDKs and mitogen-activated protein kinase 1/2 (MEK 1⁄2; reviewed in [153]). The gene discussed is EGFR; the disease is neoplasm.